NEW YORK, October 5, 2017 - Today, Informa Pharma Intelligence and The Alliance for Regenerative Medicine (ARM), the preeminent global advocate for gene therapy, cell therapy and the broader regenerative medicine sector, announced an expansion to their partnership to advance awareness and understanding of regenerative medicine and its potentially transformative impact on healthcare and society.
Informa Pharma Intelligence analysts and tools provide comprehensive insight into global clinical trials, drug development pipelines and the regenerative medicine marketplace. By incorporating Informa Pharma Intelligence’s knowledge of the regenerative medicine pipeline with ARM’s sector expertise, the two organizations will work together to bring critical understanding of the quickly advancing regenerative medicine field to foster research, development, investment and commercialization of treatments for patients worldwide.
While still rapidly evolving, regenerative medicine has made huge advances in recent years both in the United States and globally. This year, for the first time, the U.S. Food and Drug Administration (FDA) approved Novartis’ cell-based immuno-oncological CAR-T therapy, clearing a new treatment that has produced unprecedented results in pediatric and young adult patients with refractory/relapse acute lymphoblastic leukemia. Others in the industry will likely soon follow. Through the partnership, Informa Pharma Intelligence and ARM will work to educate those in the space and the broader public, in an effort to define the new field and broaden awareness of its immense value, potential to improve health outcomes and significant societal benefits.
Michael Hay, Head of Intelligence Products of Informa Pharma Intelligence commented, “This is an exciting time for the regenerative medicine field, with new advancements happening rapidly. We have partnered with ARM for more than three years, and we welcome the opportunity to continue our collaboration with an organization as influential and forward-thinking as ARM. Our goal is to expand education and awareness to key stakeholders in the space, as well as the wider public who will benefit from these new treatments.”
Morrie Ruffin, Managing Director, ARM added, “We have, for several years, partnered with Informa Pharma Intelligence, gaining access to their immense data assets and jointly building a robust resource to track performance of the field of regenerative medicine sector and help advance understanding and build awareness of its accomplishments.”
Informa Pharma Intelligence and ARM are together at the Cell & Gene Therapy Meeting on the Mesa this week, taking place October 4-6. Coming up, Informa Pharma Intelligence and ARM will host a joint webinar on October 24th to answer the question of what’s next after the CAR-T approval. Sign up to attend the free webinar here.
Informa Pharma Intelligence powers a full suite of analysis products including Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo, to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers.
Datamonitor Healthcare, powered by Informa Pharma Intelligence, is part of the wider Informa Business Intelligence brand that provides insight into six core industries - Pharma & Healthcare; Agribusiness & Commodities; Finance; Telecoms, Media & Technology; Maritime & Law; Infrastructure.
For more information visit pharmaintelligence.informa.com.
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 270 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
For more information, please contact:
Allie Tedone/Danielle Cecchini